JIMD Reports
DOI 10.1007/8904_2018_138
RESEARCH REPORT
Dihydropyrimidine Dehydrogenase Deficiency:
Homozygosity for an Extremely Rare Variant in DPYD due
to Uniparental Isodisomy of Chromosome 1
André B. P. van Kuilenburg • Judith Meijer •
Rutger Meinsma • Belén Pérez-Dueñas •
Marielle Alders • Zahurul A. Bhuiyan • Rafael Artuch •
Raoul C. M. Hennekam
Received: 23 July 2018 / Revised: 17 August 2018 / Accepted: 20 August 2018 / Published online: 23 October 2018
# Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018
Abstract Dihydropyrimidine dehydrogenase (DPD)
deficiency is a rare autosomal recessive disorder of the
pyrimidine degradation pathway and can lead to intellectual
disability, motor retardation, and seizures. Genetic variations in DPYD have also emerged as predictive risk factors
for severe toxicity in cancer patients treated with fluoropyrimidines. We recently observed a child born to nonconsanguineous parents, who demonstrated seizures, cognitive impairment, language delay, and MRI abnormalities
and was found to have marked thymine-uraciluria. No
residual DPD activity could be detected in peripheral blood
mononuclear cells. Molecular analysis showed that the
child was homozygous for the very rare c.257C > T (p.
Pro86Leu) variant in DPYD. Functional analysis of the
recombinantly expressed DPD mutant showed that the DPD
mutant carrying the p.Pro86Leu did not possess any
Communicated by: Jörn Oliver Sass
A. B. P. van Kuilenburg (*) : J. Meijer : R. Meinsma : M. Alders :
R. C. M. Hennekam
Amsterdam UMC, University of Amsterdam, Departments of Clinical
Chemistry, Genetics and Pediatrics, Amsterdam Gastroenterology &
Metabolism, Amsterdam, The Netherlands
e-mail: a.b.vankuilenburg@amc.uva.nl
B. Pérez-Dueñas : R. Artuch
Departments of Neuropediatrics and Clinical Biochemistry, Institut de
Recerca Sant Joan de Déu, CIBERER-ISCIII, Barcelona, Spain
B. Pérez-Dueñas
Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de
Barcelona, Barcelona, Spain
Z. A. Bhuiyan
Service de Médecine Génétique, Laboratoires de Médecine Génétique,
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
residual DPD activity. Carrier testing in parents revealed
that the father was heterozygous for the variant but
unexpectedly the mother did not carry the variant. Microsatellite repeat testing with markers covering chromosome
1 showed that the DPD deficiency in the child is due to
paternal uniparental isodisomy. Our report thus extends the
genetic spectrum underlying DPYD deficiency.
Introduction
Dihydropyrimidine dehydrogenase (DPD) is the initial and
rate-limiting enzyme of the pyrimidine degradation pathway, catalyzing the reduction of uracil and thymine to 5,6dihydrouracil and 5,6-dihydrothymine, respectively. In
patients with a complete DPD deficiency (MIM 274270),
a considerable variation in the clinical presentation has been
observed ranging from severely (neurologically) affected to
symptomless. Therefore, a DPD deficiency is probably a
necessary, but not a sole prerequisite for the onset of a
clinical phenotype (Fleger et al. 2017; van Kuilenburg et al.
1999). Delayed cognitive and motor development and
convulsive disorders are relatively frequent manifestations,
whereas growth retardation, microcephaly, dysmorphia,
autism, hypotonia, and ocular abnormalities are less
frequently observed (Chen et al. 2014; Enns et al. 2004;
van Kuilenburg et al. 1999, 2002a, 2009). In addition,
patients with a DPD deficiency have a strongly reduced
capacity to degrade the widely used chemotherapeutic drug
5-fluorouracil and, therefore, an increased likelihood of
suffering from severe and sometimes fatal multi-organ
toxicity (Johnson and Diasio 2001; van Kuilenburg 2004).
66
DPYD is present as a single copy gene on chromosome
1p21.3 and consists of 23 exons (Wei et al. 1998). A large
number of variants have been described in DPYD including
large genomic deletions and amplifications (van Kuilenburg
et al. 2009). The identification of novel disease-causing
genomic aberrations is important to allow analysis of
genotype-phenotype relationships in DPD-deficient patients
and screening of cancer patients at risk. Our study
identified a novel genetic mechanism underlying DPD
deficiency, and we present the first patient with a complete
DPD deficiency due to paternal uniparental isodisomy of
chromosome 1.
Materials and Methods
Sequence analysis of DPYD, including analysis of intragenic rearrangements, was carried out essentially as
described before (van Kuilenburg et al. 2017). Analysis of
pyrimidine metabolites was performed using reversedphase HPLC combined with electrospray tandem-mass
spectrometry (van Lenthe et al. 2000). Functional expression of a DPYD mutation in mammalian HEK293 Flp-In
cells and subsequent analysis of recombinantly expressed
DPD protein levels and DPD activity were performed as
described before (van Kuilenburg et al. 2017).
Twenty six microsatellite repeat markers spreading over
the full length of chromosome 1 were used for haplotype
analysis. These included 21 markers from ABI-Prism
Linkage Mapping Set MD panels 1 and 2 (PE Biosystems,
Foster City, CA, USA) and 5 additional markers: D1S2775,
D1S2719, D1S2793, D1S415, and D1S2753 (NCBI,
UniSTS). After PCR, the amplified fragments were separated using the ABI Prism 377 automatic DNA sequencer
(PE Biosystems, Foster City, CA, USA), and the length of
the fragments was analyzed with GeneMapper software (PE
Biosystems, Foster City, CA, USA).
Results
Case Report
The female patient was the first child of non-consanguineous Portuguese parents. Developmental delay was noticed
during the second year of life: she walked unassisted at the
age of 20 months and showed language delay. At the age of
3 years, she started to have seizures. Despite treatment with
valproic acid and carbamazepine, she continued to have
seizures every few weeks to months. A neuropsychological
study at 5 years and 8 months using the McCarthy Scales of
Children’s Abilities (MSCA) showed significantly reduced
scores [verbal, 22; perceptual performance, 22; quantitative,
22; memory, 25; motor, 24 (controls: mean standard
deviation 50 10); and general cognitive index, 50
JIMD Reports
(controls: mean standard deviation 100 15)]. Neurological examination at the age of 7 years revealed a nondysmorphic child with normal growth and head circumference and poor fine and gross motor coordination. She was
socially engaging and showed cognitive impairment and
language delay. Magnetic resonance imaging (MRI) demonstrated symmetrically enlarged lateral ventricles and a
thin corpus callosum. Cerebral white matter signal was
normal. EEG showed generalized slow wave discharges
with maximal amplitude in frontal lobes and poor organization of background activity. At 10 years, the Peabody
Picture Vocabulary Test-IV (PPVT-IV) revealed markedly
low verbal abilities (verbal age 4 years and 4 months). An
attempt to withdraw valproic acid at 10 years increased
epileptic activity. Currently, the patient is 12 years old, and
she has adapted to a mainstream school with the support of
special education teachers and speech therapy. She suffers
from occasional partial and secondarily generalized tonicclonic seizures. Background activity on EEG recording has
normalized, and no paroxysms are registered.
Biochemical and Genetic Studies
As part of a screening for inborn errors of metabolism,
purines and pyrimidines were analyzed in urine and plasma.
Strongly elevated concentrations of uracil and thymine
were observed in urine and plasma which suggested that the
patient had a DPD deficiency (Table 1). Subsequent
analysis showed no residual DPD activity in peripheral
blood mononuclear cells. Sequence analysis of DPYD
showed that the patient was homozygous for the c.257C > T
(p.Pro86Leu) variant (Table 1). Expression of the mutant
DPYD construct containing the c.257C > T (p.Pro86Leu)
variant in HEK293 Flp-In cells showed that the DPD
mutant carrying the Pro86Leu variant possessed hardly any
residual activity (0.7%) compared to the wild-type enzyme
(Fig. 1). To exclude the possibility that the lack of DPD
activity was the result of an inability to produce the mutant
DPD protein in HEK293 Flp-In cells, the DPD protein
expression levels were analyzed by immunoblotting. Figure
1 shows that the mutant DPD protein, carrying the
Pro86Leu variant, was expressed in a comparable amount
as the wild-type protein. Thus, the lack of DPD activity of
the mutant DPD enzyme in HEK293 Flp-In cells is not due
to rapid degradation of the mutant DPD protein in the
HEK293 Flp-In lysates.
DNA sequence analysis in the father demonstrated that
he was heterozygous for the c.257C > T variant in DPYD,
but in the mother the variant could not be detected. DPYD
is prone to acquire genomic rearrangements due to the
presence of an intragenic fragile site FRA1E, but MLPA
analysis showed no intragenic deletions or amplifications of
DPYD in the patient or parents. Haplotype analyses with 26
JIMD Reports
67
Table 1 Biochemical and genetic analysis of a DPD-deficient patient
Urine (mmol/mmol creatinine)
Plasma (mM)
Subject
Uracil
Thymine
Uracil
Thymine
DPD activity [nmol/(mg total protein h)]
DPYDa
Patient
236
131
13.4
15.2
<0.025
c.257[C > T];[C > T]
Father
n.a.
n.a.
n.a.
n.a.
n.a.
c.257[C > T];[¼]
Mother
n.a.
n.a.
n.a.
n.a.
n.a.
c.257C¼
9.9 2.8 (n ¼ 54)b
Controls
Median
5
<1
0.19
0.04
Range
1–35 (n ¼ 112)
<1 (n ¼ 112)
0.08–0.36 (n ¼ 100)
0.02–0.09 (n ¼ 100)
n.a. not available
Nomenclature according to http://varnomen.hgvs.org/
b
Data taken from (van Kuilenburg et al. 2002b)
a
Fig. 1 DPD activity and immunoblot analysis of recombinantly
expressed wild-type and mutant DPD enzymes. The results represent
the relative DPD activity (mean + SD, n ¼ 3) of the DPD mutant
carrying the Pro86Leu variant compared to wild-type DPD enzyme.
The insert shows the immunoblot analysis of the expressed wild-type
and mutant DPD enzyme
microsatellite repeats distributed over chromosome 1 to
probe for homozygosity for the c.257C > T variant in
DPYD by uniparental isodisomy for chromosome 1
demonstrated the patient to be homozygous for all 26
markers (Fig. 2). Fourteen markers were uninformative
since they could have been inherited from either parent. For
one marker only paternal uniparental disomy (UPD) could
be proven. Paternal isodisomy was observed for 11 markers
(Fig. 2).
phenotype typically observed in clinically affected patients
with DPD deficiency (van Kuilenburg et al. 1999, 2002a,
2009). The MRI findings in the present patient are
nonspecific and have been reported infrequently in DPDdeficient patients (Chen et al. 2014; Enns et al. 2004).
Chromosome 1 is not known to contain imprinted areas or
imprinted genes, so UPD of chromosome 1 is not expected
to cause a phenotype by a disturbed methylation.
The frequency of UPD in newborn is considered to be 1 in
3,500–5,000 (Liehr 2010). Chromosomes 7, 11, 14, 15, and
16 are most often involved in uniparental isodisomy
formation, and for chromosome 1 only, a moderate
frequency of uniparental isodisomy has been observed
(Liehr 2010). The c.257C > T variant (rs568132506) is
extremely rare in the general population (allele frequency
5.4 10 5 in gnomAD; http://gnomad.broadinstitute.org/
variant/1-98206012-G-A). So far, this variant has been
described in only one patient with a complete DPD
Discussion
Dihydropyrimidine dehydrogenase (DPD) deficiency is an
autosomal recessive disease characterized by thymineuraciluria in homozygous-deficient patients. Here, we
present the first case of DPD deficiency due to uniparental
isodisomy. The phenotype in the patient, i.e., cognitive
impairment, language delay, and seizures, is similar to the
68
JIMD Reports
Fig. 2 Genotype analysis of chromosome 1 using 26 microsatellite
repeats. The patient was homozygous for all 26 markers and showed
paternal uniparental isodisomy for 11 markers and paternal UPD for 1
marker, and 14 markers were uninformative. The presence of the
c.257C > T variant (M) or wild-type sequence (WT) of DPYD is
indicated for the patient and parents
deficiency (van Kuilenburg et al. 2002a). Analysis of the
crystal structure of DPD showed that Pro86 is in close
proximity to one of the iron-sulfur clusters in the N-terminal
domain (van Kuilenburg et al. 2002a). The introduction of a
leucine at this position would interfere with the binding of
the iron-sulfur cluster, thereby inhibiting electron transport
and thus activity (van Kuilenburg et al. 2002a).
The elucidation of genetic mechanisms underlying DPD
deficiency is increasingly being appreciated since DPD
deficiency has been recognized as an important determinant
of fluoropyrimidine-associated toxicity in cancer patients
(van Kuilenburg et al. 2017; van Kuilenburg 2004). To
date, many pathogenic variants have been described in
DPYD, and additional rare variants may collectively
explain an appreciable fraction of patients with DPD
deficiency. Therefore, the identification of novel genetic
mechanisms underlying DPD deficiency will not only allow
analysis of genotype-phenotype relationships in DPDdeficient patients but also screening of cancer patients at
risk. Our study showed that uniparental isodisomy should
be considered in DPD-deficient patients with only one
parent being a carrier for a pathogenic variant in DPYD.
Synopsis
The c.257C > T (p.Pro86Leu) variant in DPYD results in a
mutant DPD enzyme without residual activity, and uniparental isodisomy should be considered in DPD-deficient
patients with only one parent being a carrier for a
pathogenic variant in DPYD.
Compliance with Ethics Guidelines
Conflict of Interest
André van Kuilenburg, Judith Meijer, Rutger Meinsma,
Belén Pérez-Dueñas, Marielle Alders, Zahurul A. Bhuiyan,
Rafael Artuch, and Raoul Hennekam declare that they have
no conflict of interest.
Details of Ethical Approval
The study (W16_179 # 16.210) was approved by the
Medical Ethics Committee of the Academic Medical
Center.
JIMD Reports
Patient Consent Statement
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experimentation (institutional) and with the Helsinki Declaration
of 1975, as revised in 2000. Informed consent was obtained
from the parents of the child included in this study for
publication.
Authors’ Contribution
André van Kuilenburg and Raoul Hennekam: study design,
data analysis, and drafting of the article
Judith Meijer, Rutger Meinsma, Marielle Alders, and
Zahurul A. Bhuiyan: experimental data acquisition and data
analysis
Belén Pérez-Dueñas and Rafael Artuch: patient care and
drafting of the article
Guarantor and Corresponding Author
André B.P. van Kuilenburg accepts full responsibility for
the work and conduct of the study, had access to the data,
and controlled the decision to publish.
Details of Funding
None
References
Chen BC, Mohd Rawi R, Meinsma R, Meijer J, Hennekam RC,
van Kuilenburg AB (2014) Dihydropyrimidine dehydrogenase
deficiency in two Malaysian siblings with abnormal MRI
findings. Mol Syndromol 5(6):299–303
69
Enns GM, Barkovich AJ, van Kuilenburg ABP et al (2004)
Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 27(4):513–522
Fleger M, Willomitzer J, Meinsma R et al (2017) Dihydropyrimidine
dehydrogenase deficiency: metabolic disease or biochemical
phenotype? JIMD Rep 37:49–54
Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine
dehydrogenase (DPD) deficiency in patients exhibiting toxicity
following treatment with 5-fluorouracil. Adv Enzyme Regul
41:151–157
Liehr T (2010) Cytogenetic contribution to uniparental disomy (UPD).
Mol Cytogenet 3:8
van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase
and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40
(7):939–950
van Kuilenburg ABP, Vreken P, Abeling NGGM et al (1999)
Genotype and phenotype in patients with dihydropyrimidine
dehydrogenase deficiency. Hum Genet 104(1):1–9
van Kuilenburg ABP, Dobritzsch D, Meinsma JR et al (2002a)
Novel disease-causing mutations in the dihydropyrimidine
dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 364(Pt 1):157–163
van Kuilenburg ABP, Meinsma JR, Zoetekouw L, van Gennip AH
(2002b) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase
deficiency: high prevalence of the IVS14+1g>a mutation. Int J
Cancer 101(3):253–258
van Kuilenburg ABP, Meijer J, Mul ANP et al (2009) Analysis of
severely affected patients with dihydropyrimidine dehydrogenase
deficiency reveals large intragenic rearrangements of DPYD and
a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet
125(5–6):581–590
van Kuilenburg AB, Meijer J, Maurer D et al (2017) Severe
fluoropyrimidine toxicity due to novel and rare DPYD missense
mutations, deletion and genomic amplification affecting DPD
activity and mRNA splicing. Biochim Biophys Acta 1863
(3):721–730
van Lenthe H, van Kuilenburg ABP, Ito T et al (2000) Defects in
pyrimidine degradation identified by HPLC-electrospray
tandem mass spectrometry of urine specimens or urine-soaked
filter paper strips. Clin Chem 46(12):1916–1922
Wei X, Elizondo G, Sapone A et al (1998) Characterization of the
human dihydropyrimidine dehydrogenase gene. Genomics 51
(3):391–400